Page last updated: 2024-08-21

isonicotinamide and Melanoma

isonicotinamide has been researched along with Melanoma in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Almeida, AA; Boroni, M; Bressan, GC; Caetano, MMM; de Andrade Barros, MV; de Oliveira Santos, L; de Oliveira, LL; de Paiva, JC; de Souza, APM; do Vale, JA; Fietto, JLR; Gonçalves, VHS; Guimarães, GR; Machado-Neves, M; Martim, FRG; Moreira, GA; Silva, LVG; Silva-Júnior, A; Teixeira, RR1

Other Studies

1 other study(ies) available for isonicotinamide and Melanoma

ArticleYear
The SRPK inhibitor N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl) isonicotinamide (SRPIN340) increases the immune response against metastatic melanoma in mice.
    Biochemical pharmacology, 2022, Volume: 203

    Topics: Animals; Humans; Immunity; Melanoma; Mice; Niacinamide; Piperidines; Protein Serine-Threonine Kinases; Skin Neoplasms; Tumor Microenvironment

2022